Mounjaro vs. retatrutide: what patients need to know in 2026

What is retatrutide?

Retatrutide is an investigational once-weekly injection that acts on three gut-hormone receptors at once — GLP-1, GIP and glucagon — one step beyond Mounjaro (tirzepatide), which acts on two. It is still in late-stage clinical trials and is not yet approved anywhere in the world, which means it cannot be legally prescribed or sold.

How does retatrutide's weight loss compare to Mounjaro's?

The weight loss is broadly similar, with retatrutide trending slightly higher. In clinical trials, retatrutide produced around 24% total body weight loss at 48 weeks, while tirzepatide (Mounjaro) produced around 20% over a longer period. The difference is real but smaller than headlines suggest — and it comes with trade-offs described below.

Does retatrutide cause more muscle loss?

This is a genuine concern. Faster and deeper weight loss generally carries a higher proportion of lean-mass (muscle) loss, and the glucagon component of retatrutide increases energy expenditure in ways that make protecting muscle even more important. Losing muscle harms your metabolism, strength and long-term weight maintenance — which is why any powerful obesity medication must be paired with adequate protein and resistance training under supervision.

What about side effects?

Retatrutide's side-effect burden in trials was higher than what we typically see with Mounjaro: more nausea, vomiting and other digestive symptoms, and increases in heart rate that require monitoring. Mounjaro's side effects are well characterized after years of real-world use; retatrutide's full safety picture is still being written by the ongoing trials.

Can I buy retatrutide now?

No — and please do not try. Because retatrutide is unapproved, there is no legitimate pharmacy supply anywhere. What is sold online, on social media, or through "research peptide" websites is black-market product: unregulated vials with no guarantee of purity, sterility, correct dosing — or of containing retatrutide at all. Analyses of seized counterfeit weight-loss injections have repeatedly found wrong doses, bacterial contamination and completely different substances.

What are the real risks of black-market retatrutide?

You risk infection from non-sterile vials, dangerous overdosing or underdosing, allergic reactions to unknown impurities, and taking an unmonitored drug that raises heart rate without any medical oversight. You also lose every safety net: no screening for contraindications, no dose titration, no follow-up. No amount of potential weight loss justifies injecting an unverified substance.

When will retatrutide become available?

If the ongoing phase-3 trials confirm its safety and efficacy, approval by regulators such as the FDA would follow, and availability in our region after that. When it is approved, Professor Jamal's obesity medications clinic will offer it with proper screening and monitoring — exactly as it did among the first in the region with Mounjaro.

What should I do today if I want serious medical weight loss?

Use what is approved, proven and supervised: Mounjaro (tirzepatide) and Wegovy (semaglutide) deliver excellent, well-studied results — around 15–20% total body weight loss — inside a program that protects your muscle, manages side effects and plans for maintenance. Waiting for retatrutide while doing nothing, or gambling on black-market vials, are both worse strategies than starting proper treatment now.

Is switching to retatrutide later possible?

Yes. Patients established on Mounjaro or Wegovy can be reassessed when new medications are approved, and switching strategies will be guided by evidence as it matures. Obesity treatment is a long-term partnership, not a one-time choice.

How do I get properly assessed?

Book a consultation at Professor Jamal's obesity medications clinic, Kuwait Hospital, Sabah Al-Salem — WhatsApp +965 60621662 or phone +965 22207777 — or online from anywhere via the DAWI app. Professor Jamal holds the American Board of Obesity Medicine and published some of the region's first research on Mounjaro.

This article is educational and does not replace personalized medical advice.